What is Opticyte?
Opticyte is at the forefront of medical device innovation, having developed the VitalO₂, a pioneering device capable of real-time intracellular oxygen level measurement. This technology is poised to revolutionize the standard of care for critical conditions such as sepsis and organ failure, with a particular focus on addressing healthcare disparities affecting people of color. The VitalO₂ is designed for deployment in high-acuity settings including emergency departments, intensive care units, and operating rooms, providing clinicians with vital, actionable data for early detection and intervention. The company's mission is deeply rooted in saving lives and advancing health equity through technological advancement.
How much funding has Opticyte raised?
Opticyte has raised a total of $4.6M across 2 funding rounds:
Grant
$2.9M
Angel/Seed
$1.7M
Grant (2020): $2.9M with participation from SBIR Phase IIB
Angel/Seed (2020): $1.7M led by SWAN Venture Fund II and Starfish Medical
Key Investors in Opticyte
SWAN Venture Fund II
SWAN Venture Fund II is an investment entity that likely focuses on early-stage companies with disruptive technologies, potentially within the healthcare or deep tech sectors.
Starfish Medical
Starfish Medical is a contract manufacturer and product development firm specializing in medical devices, indicating a strategic partnership for product realization and market readiness.
SBIR Phase IIB
SBIR Phase IIB represents a government grant awarded to small businesses for research and development, signifying validation of Opticyte's technological innovation and potential for commercialization.
What's next for Opticyte?
With substantial backing and a clear strategic direction, Opticyte is well-positioned for its next phase of growth. The company's focus on transforming critical care diagnostics and addressing health disparities suggests a trajectory aimed at scaling production, expanding clinical validation, and pursuing regulatory approvals. Future investment will likely fuel further research and development, market penetration, and strategic partnerships to integrate the VitalO₂ technology into mainstream healthcare protocols, thereby enhancing patient outcomes and solidifying its market leadership in cellular diagnostics.
See full Opticyte company page
